ArticleOral oncology2025
Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
Article in Oral oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging histopathology, inferred transcriptomics, and immunotherapy response prediction in head and neck cancer.Translational cancer research · 2026Article
- Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomics.Frontiers in immunology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmune checkpoint inhibitors (ICI) prolong survival in advanced head and neck squamous cell carcinoma (HNSCC), yet response remains widely varied, necessitating more accurate and applicable biomarkers. We present a retrospective analysis of ENLIGHT-DP, a novel transcriptome-based biomarker applied directly on histopathology slides, in HNSCC patients treated with first-line programmed death (PD)-1 inhibitors.
methodsWe retrospectively scanned high-resolution hematoxylin and eosin (H&E) slides from pre-treatment tumor-tissue samples of advanced HNSCC treated with first-line ICI and applied our ENLIGHT-DP pipeline to generate an individual prediction score. ENLIGHT-DP is composed of two steps: (i) predict individual mRNA expression directly from H&E scanned slides using DeepPT, a digital-pathology based algorithm. (ii) Use these values as input to ENLIGHT, a transcriptome-based platform that predicts response to ICI and targeted therapies. We then unblinded the clinical outcomes and evaluated the predictive value of ENLIGHT-DP in comparison to combined positive score (CPS).
resultsWe evaluated 25 patients with advanced HNSCC treated with first-line PD-1 inhibitors as monotherapy (15/25) or in combination with chemotherapy (10/25). In patients treated with monotherapy, ENLIGHT-DP predicts response to ICI with ROC AUC of 0.74 while CPS is not predictive. Utilizing a predetermined binary cutoff (established on independent cohorts), ENLIGHT-DP achieves 75% positive predictive value (PPV), which is superior to CPS. ENLIGHT-DP was also predictive of response to treatment in the entire patient cohort.
conclusionENLIGHT-DP accurately predicts response to PD-1 inhibitors treatment in HNSCC, especially in patients receiving ICI monotherapy and relying solely on easily accessible H&E scanned slides.
Indexed as
Identifiers
40743912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.